NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

CARDIEX LIMITED (CDX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

Shareholder links

Our website ranking of CDX: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000015729
Address: Suite 301, 55 Lime Street, Sydney NSW 2000
Tel:  (02) 9874 8761Fax: (02) 9874 9022

Date first listed: 09/11/2005
Company Secretary: Louisa Ho
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: The development and marketing of the SphygmoCor device used for cardiovascular patient assessment and management

News & Events

Expand this box to read and print

The suspension of trading in the securities of CardieX Limited is expected to be lifted from the commencement of trading on Monday, 26 February 2024 following its compliance with Listing Rules 12.1 and 12.2.

23/02/2024

The company releases pro-forma consolidated statement of financial position for 31 December 2023 (reinstatement disclosure).

23/02/2024

The company releases a reinstatement disclosure, the pro forma balance sheet.

23/02/2024

The company releases a notification of cessation of securities.

19/02/2024

The company releases its Top 20 and Distribution Schedule - Listed Options.

12/02/2024

The company releases a notice of application for quotation of securities.

07/02/2024

Non-Renounceable Pro-Rata Entitlement Offer (partially underwritten) raises $4 million (before costs). Valid applications under the Shortfall and Top-Up Facility to be honoured in full. $0.9 million (of $1 million underwriting) taken up by the Underwriter (C2 Ventures "“ jointly owned by Chairman, Niall Cairns & CEO, Craig Cooper). Total Capital Raising of $8 million ($4 million Institutional Placement and $4 million Entitlement Offer) now complete. New shares and options under the Entitlement Offer will be issued 7 February 2024. Continued progress being made and liaisons with ASX underway as to the reinstatement of trading in the Company's shares.

06/02/2024

The company releases a notification regarding unquoted securities.

06/02/2024

The company releases a notice of application for quotation of securities.

06/02/2024

The company releases the results of its meeting.

01/02/2024

The company releases a notice of proposed issue of securities.

31/01/2024

$4 million Entitlement Offer will close at 5:00pm (AEDT) on Thursday, 1 February 2024. $4.3 million 31 December 2023 cash balance. Cash balance to increase with Institutional Placement and Entitlement Offer proceeds.

30/01/2024

The company lodges its December Quarterly Activities Report.

29/01/2024

The company lodges its December Quarterly Appendix 4C.

29/01/2024

The company releases its January 2024 Webinar Presentation.

18/01/2024

The company releases a Supplementary Prospectus for Entitlement Offer.

18/01/2024

The company releases a notification of cessation of securities.

15/01/2024

The Company will host an investor webinar on Thursday, 18 January 2024 at 11:00am (AEDT)/Wednesday, 17 January 2024 at 4:00pm (PDT). The webinar will be hosted by CardieX's CEO Craig Cooper, Executive Chairman Niall Cairns, and Chief Strategy Officer Catherine Liao, who will be providing an update on the Company's business activities following recent Company announcements. Registration: https://us06web.zoom.us/webinar/register/WN_vhKmLTswTE29QFtMpC9BNw.

15/01/2024

An Extraordinary General Meeting has been called for 9:30am (AEDT) on Thursday, 1 February 2024. The meeting is to be held at 24-26 Kent Street, Millers Point NSW 2000.

04/01/2024

Following the launch of the Company's $4 million placement and pro rata entitlement offer of up to $4 million, in each case with attaching quoted options, the Company has been able to progress discussions with ASX as to lifting the suspension in trading of the Company's shares which has been in place since 28 September 2023.

02/01/2024

The Company has completed the despatch of the prospectus dated 19 December 2023 for its nonrenounceable pro-rata entitlement offer of 1 new fully paid ordinary share for every 2.87 existing Shares held by eligible shareholders at an issue price of $0.08 per new Share, together with 1 quoted option for every 3 new Shares subscribed for and issued, to raise up to approximately $4.0 million.

29/12/2023

The company provides a revised timetable for the prospectus released to the ASX on 19 December 2023.

20/12/2023

The company releases an updated notice of proposed issue of securities.

20/12/2023

The company releases a letter regarding the entitlement offer to the ineligible shareholders.

19/12/2023

The company releases its December Investor Presentation.

19/12/2023

The company issues a prospectus for a non-renounceable pro-rata offer to Eligible Shareholders on the basis of 1 New Share for every 2.87 existing Shares held on the Record Date at an issue price of $0.08 per New Share, together with 1 Quoted Option for every 3 New Shares subscribed for and issued.

19/12/2023

The company releases a notice of proposed issue of securities.

19/12/2023

Firm commitments received to raise up to $4.0 million through a Share Placement with institutional and sophisticated investors. Share Placement to be completed in two tranches: Tranche 1 - $1.66m in gross proceeds raised before costs (settling December 2023). Tranche 2 - $2.34m in gross proceeds raised before costs (settling February 2024 following Extraordinary General Shareholder Meeting). C2 Ventures has committed $0.79 million in the Share Placement (subject to shareholder approval) as part of its previously announced $7.5 million Funding Commitment Agreement. Launch of Entitlement Offer to existing eligible shareholders on the same terms to raise up to approximately an additional $4.0 million on the same terms as the Share Placement. Prospectus and Offer Document lodged with ASIC and ASX this day to provide pathway to resumption of trading of securities and recapitalisation of Company. C2V (and Associates) to subscribe for their entitlements of up to $0.75 million in the Entitlement Offer. CardieX in a strong capital position following receipt of operational cash inflows on 7 December 2023 and with access to remaining $6.0 million under the FCA to be provided to the Company over calendar year 2024.

19/12/2023

The company releases a notification of cessation of securities.

18/12/2023

The company releases a notification of cessation of securities.

12/12/2023

The Company has today received US$4.12 million (~A$6.26 million1 ), being the full settlement of all contractual payments in relation to the Clinichain clinical trial.

07/12/2023

The company releases its Amended Constitution.

30/11/2023

The company releases the results of its meeting.

30/11/2023

The company releases its AGM Executive Update.

30/11/2023

Mitchell Asset Management extends loan expiration of R&D Facility and Working Capital Facility beyond current calendar year. Progress in claim of ~$750k Research and Development Tax Incentive Grant for the 2023 year which will be used to repay MAM facility. Largest single creditor Wilson Sonsini Goodrich & Rosati rovides signed credit note and waiver to fees of over $1,000,000. Further financial accommodation by WSGR through promissory note and payment terms for majority of US listing related costs. Overall restructure represents significant balance sheet improvement in conjunction with recently announced Funding Commitment Agreement ith C2 Ventures for up to $7.5m.

20/11/2023

Funding Commitment Agreement signed with C2 Ventures for up to $7.5 million, including C2V's participation of up to $1.5 million in the Placement and Entitlement Offer. The FCA will cornerstone a Capital Raising Package to provide the capital required to deliver significant growth and the path to profitability. Completion of the total Capital Raising Package is expected to be announced shortly and will include as follows: A Placement (with C2V participation of up to $1 million); A pro-rata Entitlement Offer to shareholders (with C2V commitment being the balance between C2V's participation in the Placement and $1.5 million); and $6 million from C2V in 2024 under the FCA. The Placement, Entitlement Offer and shares issued to C2V under the FCA will be on the same pricing and terms (subject to shareholder approval).

09/11/2023

The company releases its 2023 Appendix 4G and Corporate Governance Statement.

09/11/2023

The company lodges its 2023 Annual Report.

09/11/2023

The company lodges its September Quarterly Activities Report.

01/11/2023

The company lodges its September Quarterly Appendix 4C.

01/11/2023

The company's Annual General Meeting has been called for 9:30am AEDT on Thursday, 30 November 2023. The meeting is to be held at 24-26 Kent Street, Millers Point NSW 2000.

30/10/2023

The company releases its go-to-market and product development update. With the FDA clearance of the Pulse, the company has switched their primary focus away from regulatory and engineering to their go-to-market strategy with a focus on sales and market development. The short-term focus is on key traditional markets with their clinician, pharmaceutical company, and research partners. The longer strategy involves integrating their products and solutions across multiple new healthcare sectors, with a focus on industry sectors that rely on healthcare risk management.

09/10/2023

The company lodges its Corporate & Operating Update.

04/10/2023

The company releases its Corporate Presentation.

29/09/2023

The securities of CardieX Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding its capital raising and annual report for the year ended 30 June 2023.

28/09/2023

The suspension of trading in the securities of CardieX Limited will be lifted immediately following the release by CDX of an announcement regarding its finalisation of a material contract in relation to its clinical trial revenue.

09/12/2022

New Clinical Trial Services Agreement for the provision of XCEL devices and data management services by CardieX subsidiary ATCOR. First 2 purchase orders now received. Trial is currently scheduled for multiple sites around the globe. Anticipated trial duration of ~30 months will cornerstone CardieX's revenue for the coming 2-3 financial years.

09/12/2022

The securities of CardieX Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding the finalisation of a material contract in relation to its clinical trial revenue.

08/12/2022

The securities of Cardiex Limited will be reinstated to Official Quotation as from the commencement of trading on Tuesday, 2 February 2021 following lodgement of its Appendix 4C for the quarter ended 31 December 2020.

01/02/2021

The company lodges its Appendix 4C and Quarterly Activities Report.

01/02/2021

The securities of the entity will be suspended from Official Quotation in accordance with Listing Rule 17.5 from the commencement of trading today, 1 February 2021, following their failure to lodge the relevant periodic report by the due date.

01/02/2021

The suspension of trading in the securities of Cardiex Limited will be lifted immediately following the release by CDX of an announcement regarding its progress in relation to a joint development agreement with a partner organisation.

24/04/2020

ATCOR has this week completed a significant milestone in its engineering & technology program and has derived a series of unique and heart and arterial health features from a PPG sensor based on the Company's core SphygmoCor technology. Significant technology development milestone of wearable sensor technology for clinical and consumer applications. Technology will aim to assist in effective remote diagnosis and monitoring of hypertension and cardiovascular disease. Results to be shortly presented to ATCOR wearables partner Mobvoi, Google's official partner in China for Google's Wear OS platform. ATCOR has also been requested to demonstrate results to several major consumer wearable & technology companies.

24/04/2020

The securities of Cardiex Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding its progress in relation to a joint development agreement with a partner organisation.

22/04/2020

The suspension of trading in the securities of CardieX Limited will be lifted immediately following the release by CDX of an announcement regarding a customer contract.

18/06/2019

The company has determined that the GEMDC customer contract is material to inHealth but is not currently material to CardieX. The basis of this decision is by virtue of CardieX's current equity position in inHealth (7.7%), which is prior to conversion of the currently subscribed tranche 2 convertible note, that will increase CardieX's position to 41.03% prior to the tranche 3 option to increase this stake to 50.5%.

18/06/2019

The securities of CardieX Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding a customer contract.

17/06/2019

name changed from Atcor Medical Holdings Limited

18/06/2018

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    12/01/2021Niall Cairns1,010,475$0.049$49,292
    05/10/2020Niall Cairns589,525$0.048$28,012
    25/09/2013Michael O'Rourke-100,000$0.170$17,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Niall CairnsNon Exec Chairman20/12/2017
    King NelsonIndependent Director14/10/2015
    Charlie TaylorIndependent Director01/03/2024
    Aubrey JenkinsNon Exec Director01/02/2019
    Michelle AlencarNon Exec Director01/02/2019
    Craig CooperExecutive Director, CEO01/12/2017

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Lesa MusattoNon Exec Director27/04/202218/10/2023
    Jarrod WhiteDirector, CFO31/03/201826/09/2023
    Reid YeomanCFO06/01/202330/06/2023
    Donal O'DwyerNon Exec Chairman09/11/200526/02/2019
    Duncan RossCEO09/11/200601/07/2018
    David BrookesNon Exec Director04/11/200803/04/2018
    Peter ManleyCFO01/03/200531/03/2018
    Michael O'RourkeNon Exec Director06/11/200530/11/2017
    Peter JenkinsNon Exec Director09/11/200513/11/2015
    Lisa McIntyreNon Exec Director09/11/200504/11/2008
    Ross HarricksExecutive Director07/03/200514/11/2007

    Date of first appointment, title may have changed.